SCHEMBL3316802

SCHEMBL3316802

Brc1cc2cnccc2cc1SC1CCN(Cc2ccc3ccccc3c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.49
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.42
SIGMAR1 Q99720 1/20 0.41
MCHR1 Q99705 1/20 0.41
DRD4 P21917 1/20 0.41
PKM P14618 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
ROCK2 O75116 2/20 0.41
CYP19A1 P11511 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3311613 0.92 ROCK2 (0.46) ACHEKMT2ASIGMAR1DRD4ROCK2
SCHEMBL3311507 0.88 ROCK2 (0.42) ACHEKMT2AMEN1MCHR1DRD4
SCHEMBL3316973 0.87 ROCK2 (0.48) ACHESIGMAR1DRD4HDAC8ROCK2
SCHEMBL3319720 0.85 ROCK2 (0.38) ROCK2ROCK1
SCHEMBL3314976 0.85 ACHE (0.46) ACHEKMT2AMEN1HDAC1HDAC8
SCHEMBL3315940 0.85 CYP3A4 (0.47) ACHEDRD4ROCK2
SCHEMBL3316860 0.84 L3MBTL1 (0.42) KMT2ASIGMAR1DRD4OPRM1
SCHEMBL3311302 0.84 IKBKB (0.38) ROCK2ROCK1
SCHEMBL3313089 0.84 ROCK2 (0.46) ACHEKMT2AMEN1SIGMAR1DRD4
SCHEMBL3315859 0.83 IKBKB (0.37) ACHEKMT2AMEN1ROCK2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
EP-2114920-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-11-11 EP disclosed
WO-2008077552-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 ACHE 2527/4885KMT2A 2487/4885MEN1 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.